EcoDrugPlus

Heat Shock Protein 90 Alpha Family Class B Member 1

Ensembl ID : ENSMLEG00000024522
Gene Symbol: HSP90AB1
3 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Heat Shock Protein Hsp 90-Alpha-Like

Ensembl ID : ENSMLEG00000036254
Gene Symbol: LOC105538379
1 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H1

Ensembl ID : ENSMLEG00000027693
Gene Symbol: HRH1
4 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H2

Ensembl ID : ENSMLEG00000034345
Gene Symbol: HRH2
4 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H3

Ensembl ID : ENSMLEG00000027666
Gene Symbol: HRH3
2 Cross references
117 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histamine Receptor H4

Ensembl ID : ENSMLEG00000030717
Gene Symbol: HRH4
4 Cross references
105 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 1 Pseudogene

Ensembl ID : ENSMLEG00000037884
Gene Symbol: LOC105529488
1 Cross references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 11

Ensembl ID : ENSMLEG00000038310
Gene Symbol: HDAC11
4 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 2

Ensembl ID : ENSMLEG00000040672
Gene Symbol: HDAC2
4 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 3

Ensembl ID : ENSMLEG00000038000
Gene Symbol: HDAC3
4 Cross references
156 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 4

Ensembl ID : ENSMLEG00000036591
Gene Symbol: HDAC4
4 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Histone Deacetylase 5

Ensembl ID : ENSMLEG00000036576
Gene Symbol: HDAC5
4 Cross references
194 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).